Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.49 |
| ▸ | OXTR | P30559 | 2/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147423 | 0.87 | HRH3 (0.53) | CHRM4HRH3 | |
| SCHEMBL20147449 | 0.82 | HRH3 (0.47) | CHRM4OXTRAVPR1AHRH3ACACB | |
| SCHEMBL20069570 | 0.80 | CHRM4 (0.53) | CHRM4OXTRAVPR1AHRH3 | |
| SCHEMBL20069585 | 0.78 | HRH3 (0.55) | HRH3 | |
| SCHEMBL25502660 | 0.77 | OGA (0.53) | CHRM4 | |
| SCHEMBL28603785 | 0.76 | PDGFRB (0.49) | CHRM4OXTRAVPR1AACACBACACA | |
| SCHEMBL20069133 | 0.76 | CHRM4 (0.49) | CHRM4OXTRAVPR1AHRH3 | |
| SCHEMBL20069143 | 0.76 | OXTR (0.43) | CHRM4OXTRAVPR1AACACBACACA | |
| SCHEMBL19023669 | 0.74 | CHRM4 (0.51) | CHRM4OXTRAVPR1A | |
| SCHEMBL22856983 | 0.74 | OXTR (0.41) | CHRM4OXTRAVPR1AACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CHRM4 2166/4885OXTR 3773/4885AVPR1A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.